Answers are grounded in this paper and cite their sources.
While existing clinical studies are open to bias and intrinsically limited, the meta-analysis dilutes the risk of bias by weighting more precise evidence, providing the highest quality evidence to date. Further research is essential to understand teprotumumab's long-term efficacy and comparative advantages over surgical options. These findings have significant implications for treating persistent proptosis in patients with long-duration TED, potentially offering a non-surgical alternative where options were previously limited.
No takes yet. Share an insight, caveat, or question.
Householder et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: